Damora Therapeutics is an innovative biotechnology company developing novel subcutaneous biologics for mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis. Its lead program, DMR-001, is an investigational monoclonal antibody targeting mutant calreticulin.